Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi versus insulin glargine for brain insulin sensitivity in type 2 diabetes
2018-003557-21Phase 4Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of insulin glargine and lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Change in brain insulin sensitivity. Started Oct 2018; status: terminated.
02
Drugs
insulin glarginelixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-003557-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003557-21.